LLY

719.07

-1.33%↓

JNJ

153.06

-0.41%↓

ABBV

183.01

+0.38%↑

NVO

68.41

+0.06%↑

UNH

298.12

-2.48%↓

LLY

719.07

-1.33%↓

JNJ

153.06

-0.41%↓

ABBV

183.01

+0.38%↑

NVO

68.41

+0.06%↑

UNH

298.12

-2.48%↓

LLY

719.07

-1.33%↓

JNJ

153.06

-0.41%↓

ABBV

183.01

+0.38%↑

NVO

68.41

+0.06%↑

UNH

298.12

-2.48%↓

LLY

719.07

-1.33%↓

JNJ

153.06

-0.41%↓

ABBV

183.01

+0.38%↑

NVO

68.41

+0.06%↑

UNH

298.12

-2.48%↓

LLY

719.07

-1.33%↓

JNJ

153.06

-0.41%↓

ABBV

183.01

+0.38%↑

NVO

68.41

+0.06%↑

UNH

298.12

-2.48%↓

Search

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

274.9 -0.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

268.74

Max

280.27

Belangrijke statistieken

By Trading Economics

Inkomsten

-14M

-73M

Verkoop

34M

137M

EPS

-3.32

Winstmarge

-53.361

Werknemers

528

EBITDA

-14M

-70M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+45.2% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-860M

6.5B

Vorige openingsprijs

275.8

Vorige sluitingsprijs

274.9

Nieuwssentiment

By Acuity

38%

62%

136 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 mei 2025, 23:25 UTC

Populaire aandelen

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 mei 2025, 21:57 UTC

Acquisities, Fusies, Overnames

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 mei 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Millicom to Acquire Telefónica's Operations in Uruguay

21 mei 2025, 21:01 UTC

Belangrijke Marktbewegers

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 mei 2025, 23:49 UTC

Marktinformatie

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 mei 2025, 23:37 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 mei 2025, 23:33 UTC

Acquisities, Fusies, Overnames

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mei 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mei 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mei 2025, 23:32 UTC

Marktinformatie
Acquisities, Fusies, Overnames

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 mei 2025, 23:31 UTC

Acquisities, Fusies, Overnames

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 mei 2025, 23:30 UTC

Acquisities, Fusies, Overnames

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 mei 2025, 23:30 UTC

Acquisities, Fusies, Overnames

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 mei 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 mei 2025, 23:28 UTC

Winsten

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 mei 2025, 23:27 UTC

Winsten

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 mei 2025, 23:26 UTC

Winsten

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 mei 2025, 23:26 UTC

Winsten

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 mei 2025, 23:26 UTC

Winsten

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 mei 2025, 23:23 UTC

Acquisities, Fusies, Overnames

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mei 2025, 23:22 UTC

Top Nieuws

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21 mei 2025, 23:22 UTC

Acquisities, Fusies, Overnames

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mei 2025, 23:20 UTC

Acquisities, Fusies, Overnames

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mei 2025, 23:18 UTC

Acquisities, Fusies, Overnames

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 mei 2025, 23:04 UTC

Top Nieuws

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21 mei 2025, 21:46 UTC

Top Nieuws

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21 mei 2025, 21:42 UTC

Top Nieuws
Acquisities, Fusies, Overnames

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 mei 2025, 21:14 UTC

Acquisities, Fusies, Overnames

Millicom to Acquire Telefónica's Ops in Uruguay

21 mei 2025, 21:07 UTC

Top Nieuws

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 mei 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

45.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 425.08 USD  45.2%

Hoogste 539 USD

Laagste 248 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

12

Buy

1

Hold

1

Sell

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

136 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.